The use of an inactivated vaccine against SARS-CoV-2, the virus that causes COVID-19, is not linked to an increased risk…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
The risk of developing another autoimmune disease, especially rheumatoid arthritis, increased in people with myasthenia gravis (MG) after surgery…
Over 40% of adults with generalized myasthenia gravis (gMG) in the U.S. who began off-label treatment with intravenous…
Nearly six months of treatment with telitacicept (RC18), an anti-inflammatory developed by RemeGen, safely lessened disease severity in adults…
Cour Pharmaceuticals is launching a Phase 1b/2a proof-of-concept study to evaluate the safety and preliminary effectiveness of its investigational…
People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19…
Long-term immunotherapy may cause anemia in female patients with myasthenia gravis (MG), according to a Japanese study that found…
Virtis Health announced that it will open two ambulatory centers in Ohio — one in Columbus and the other…
Researchers in Iran reported the first case of myasthenia gravis (MG) following a Sinopharm vaccination against SARS-CoV-2, the virus…
Researchers in Italy have reported three cases of myasthenia gravis (MG) they say may possibly have been caused by…